Bacterial ligands in complex treatment of community-acquired pneumonia in organized groups

Despite the successes achieved in treating community-acquired pneumonia (CAP), tactics still need to be  improved, especially when forming new organized collectives of military personnel.

The purpose of the study was to examine clinical and immunological features of action of an immunotropic drug of bacterial origin Immunovac-VP-4 in complex treatment of mild community-acquired pneumonia in newly recruited military personnel.

The study included 35 patients (main group 1) hospitalized with mild CAP who, in addition to basic antibacterial therapy, were treated with the Immunovac-VP-4 vaccine. Control group 2 consisted of 53 patients who received only basic antibacterial therapy. Immunovac-VP-4 contains lysates of Staphylococcus aureus, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli and was prescribed according to the nasal-subcutaneous regimen from 1 to 13 days of hospital stay. The mechanism  of action is based on activating key effectors of innate and adaptive immunity.

 In the main group there were an increase of respiratory function indicators, production of IgG antibodies to all antigens of the drug, a relative decrease in IL-6 and IFN-γ concentration in blood serum after administration of a bacterial immunomodulator.

Including the multicomponent antibacterial vaccine in subcutaneous-nasal regimen in complex treatment of mild CAP can be recommended as one of the treatment methods leading to the normalization of inflammatory mediators and the prevention of respiratory infections in this cohort of patients.

1. Russian Statistical Yearbook. Moscow, 2019. Available at: http://www.demoscope.ru/weekly/2020/0845/biblio03.php (date of access 04.12.2024) (in Russian).

2. Trifanova N. M., Leshchenko I. V. Risk factors of mortality from severe community acquired pneumonia. Ural’skii meditsinskii zhurnal [Ural medical journal], 2008, no. 13 (53), pp. 114–121 (in Russian).

3. Shaimuratov R. I. Structural analysis of the causes of deaths of patients hospitalized with community-acquired pneumonia in Tatarstan hospitals. Ph. D. Thesis. Sankt-Peterburg, 2018. 159 p. (in Russian).

4. Sibila O., Rodrigo-Troyano A., Torres A. Nonantibiotic adjunctive therapies for community-acquired pneumonia (corticosteroids and beyond): Where are we with them? Seminars in Respiratory and Critical Care Medicine, 2016, vol. 37, no. 6, pp. 913–922. https://doi.org/10.1055/s-0036-1593538

5. Yende S., D’Angelo G., Kellum J. A., Weissfeld L., Fine J., Welch R. D., Kong L., Carter M., Angus D. C. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. American Journal of Respiratory and Critical Care Medicine, 2008, vol. 177, no. 11, pp. 1242–1247. https://doi.org/10.1164/rccm.200712-1777OC

6. Wunderink R. G. Adjunctive therapy in community-acquired pneumonia. Seminars in Respiratory and Critical Care Medicine, 2009, vol. 30, no. 2, pp. 146–153. https://doi.org/10.1055/s-0029-1202933

7. Karaulov A. V. Immunology of community-acquired pneumonia. Pneumonia. Moscow, 2002, pp. 67–93 (in Russian).

8. Mukhamadieva L. R., Mavzyutova G. A., Fazlyeva R. M., Bikmetova N. R. Clinical and immunological efficiency of imunofan and polyoxidonium in combined therapy of community-acquired pneumonia. Meditsinskaya immunologiya [Medical immunology], 2009, vol. 11, no. 1, pp. 57–62 (in Russian).

9. Nascimento-Carvalho E. C., Vasconcellos Â. G., Clarêncio J., Andrade D., Barral A., Barral-Netto M., NascimentoCarvalho C. M. Evolution of cytokines/chemokines in cases with community-acquired pneumonia and distinct etiologies. Pediatric Pulmonology, 2020, vol. 55, no. 1, pp. 169–176. https://doi.org/10.1002/ppul.24533

10. Zielnik-Jurkiewicz B., Jurkiewicz D., Stankiewicz W. Effectiveness of Broncho-Vaxom in prevention of recurrent upper respiratory tract infection in children. Polski Merkuriusz Lekarski, 2005, vol. 19, no. 113, pp. 625–629 (in Polish).

11. Ababii I. I., Danilov L. A., Ginda S. S., Manyuk M. K., Ababii P. I., Kostinov M. P. Clinical and immunological efficacy of conjugated pneumococcal vaccine in children with compensated chronic tonsillitis. Pediatriya. Zhurnal imeni G. N. Speranskogo [Pediatrics. Journal named after G. N. Speransky], 2018, vol. 97, no. 2, pp. 134–139 (in Russian).

12. Foshina E. P., Kostinov M. P., Poddubikov A. V. Influence of vaccine therapy on the nasopharyngeal microbiocenosis state and evaluation of its clinical efficacy in children with chronic rhinosinusitis and tonsillopharyngitis. Pediatriya. Zhurnal imeni G. N. Speranskogo [Pediatrics. Journal named after G. N. Speransky], 2018, vol. 97, no. 2, pp. 129–133 (in Russian).

13. Kostinov M. P., Gainitdinova V. V., Kazharova S. V., Zorina V. N., Polishchuk V. B., Vlasenko A. E. The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia. Tuberkulez i bolezni legkikh [Tuberculosis and lung diseases], 2021, vol. 99, no. 4, pp. 36–43 (in Russian).

14. Herberhold S., Coch C., Zillinger T., Hommertgen B., Busch N., Schuberth C. [et al.]. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist. Antiviral Therapy, 2011, vol. 16, no. 5, pp. 751–758. https://doi.org/10.3851/IMP1822

15. Egorova N. B., Kurbatova E. A., Gruber I. M., Semenova I. B., Mikhailova N. A., Zverev V. V. Novel type of vaccine with a combination of toll like receptor agonists – TLR 1/2, 4, 5/6, 9. Zhurnal mikrobiologii, epidemiologii i immunobiologii [Journal of microbiology, epidemiology and immunobiology], 2011, no. 4, pp. 40–46 (in Russian).

16. Egorova N. B., Kurbatova E. A., Akhmatova N. K., Gruber I. M. Polycomponent vaccine immunovac-VP-4 and immunotherapeutic concept of its use for the prevention and treatment of diseases caused by opportunistic microorganisms. Zhurnal mikrobiologii, epidemiologii i immunobiologii [Journal of microbiology, epidemiology and immunobiology], 2019, no. 1, pp. 43–49 (in Russian).

17. Semenov B. F., Egorova N. B., Semenova I. B., Kurbatova E. A. Therapeutic vaccines. Rossiiskie meditsinskie vesti [Russian medical news], 2000, vol. 5, no. 3, pp. 26–32 (in Russian).

18. Egorova N. B., Kurbatova E. A. An immunotherapeutic concept of microbial antigen application in atopy and disorders associated with facultative microflora, as exemplified by a polycomponent Immunovac VP4 vaccine. Meditsinskaya immunologiya [Medical immunology], 2008, vol. 10, no. 1, pp. 13–20 (in Russian).

19. Giovannini M., Salvini F., Riva E. Bacterial extracts as immunomodulators for the prevention of recurrent respiratory infections in children. Journal of Medical Microbiology and Diagnosis, 2014, vol. 3, no. 2, art. 1000136. https://doi.org/10.4172/2161-0703.1000136

20. Shi J.-H., Li T.-S., Lin Y.-G. The evolvement of Th1/Th2 imbalance accommodates to the progress of airway inflammation in asthmatic subjects and rat model. Zhonghua Yi Xue Za Zhi, 2004, vol. 84, no. 17, pp. 1440–1444 (in Chinese).

21. Kostinov M. P., Polishchuk V. B. About the prevention of pneumococcal infections in people liable to recruitment for military service. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious diseases: news, opinions, training], 2017, no. 6 (23), pp. 37–41 (in Russian).

22. Esposito S., Marchisio P., Prada E., Daleno C., Porretti L., Carsetti R., Bosco A., Ierardi V., Scala A., Principi N. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine, 2014, vol. 32, no. 22, pp. 2546–2552. https://doi.org/10.1016/j.vaccine.2014.03.055

23. Kostinov M. P., Lavrov V. F. New generation vaccines in the prevention of infectious diseases. 2nd ed. Мoscow, Gruppa MDV Publ., 2010. 192 p. (in Russian).

24. Kostinov M. P., Svitich O. A., Markelova E. V. Potential immunoprophylaxis of COVID-19 in high-risk groups: A temporary guide for physicians. Мoscow, Gruppa MDV Publ., 2020. 64 p. (in Russian).

25. Kostinov M. P., Polishchuk V. B., Svitich O. A., Ryzhov A. A., Kostinov A. M., Tarasova A. A. [et al.]. COVID-19 vaccine prophylaxis in patients with comorbid diseases. Мoscow, Gruppa MDV Publ., 2022. 176 p. (in Russian).

26. Abramova N. D., Akhmatova N. K., Bisheva I. V., Vinnitskaya A. B., Gainitdinova V. V., Kostinov M. P. [et al.]. Mucosal immunity in patients with COVID-19: treatment and rehabilitation. Мoscow, Gruppa MDV Publ., 2022. 128 p. (in Russian).

27. Kostinov M., Svitich O., Chuchalin A., Abramova N., Osiptsov V., Khromova E. [et al.]. Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms. Drugs Contexts, 2023, vol. 12, art. 2022-10-4. https://doi.org/10.7573/dic.2022-10-4

28. Kostinov M., Svitich O., Chuchalin A., Osiptsov V., Khromova E., Abramova N. [et al.]. Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to background therapy. Journal of Clinical and Cellular Immunology, 2023, vol. 14, no. 2, p. 682. https://doi.org/10.1038/s41598-024-61341-7

29. Kostinov M. P., Tatevosov V. R., Protasov A. D., Gainitdinova V. V., Sizov A. V. Vaccination against Staphylococcus aureus and some Enterobacteriaceae in the complex treatment of mild community-acquired pneumonia in conscript servicemen. Meditsinskii vestnik MVD [MIA medical bulletin], 2021, no. 6 (115), pp. 23–29 (in Russian).

30. Kryukova N. O., Rakunova E. B., Kostinov M. P., Baranova I. A., Svitich O. A. Secretory immunoglobulin a of the respiratory system and COVID-19. Pul’monologiya [Pulmonology], 2021, vol. 31, no. 6, pp. 792–798 (in Russian).

31. Kryukova N. O., Abramova N. D., Khromova E. A., Khasanova A. A., Bisheva I. V., Skhodova S. A., Kostinov M. P., Baranova I. A., Svitich O. A., Chuchalin A. G. Bacterial ligands in the rehabilitation of healthcare workers after COVID-19. Pul’monologiya [Pulmonology], 2022, vol. 32, no. 5, pp. 716–727 (in Russian).

32. Kryukova N., Baranova I., Abramova N., Khromova E., Pachomov D., Svitich O., Chuchalin A., Kostinov M. Mucosal immunity in health care workers’ respiratory tracts in the post-COVID-19 period. Scientific Reports, 2023, vol. 1, no. 1, art. 7162. https://doi.org/10.1038/s41598-023-32670-w

33. Kryukova N. O., Kostinov M. P., Baranova I. A., Svitich O. A., Chuchalin A. G. Phagocytic activity of leukocytes of respiratory mucosa and blood in the post-COVID-19 period. Meditsinskii vestnik MVD [MIA medical bulletin], 2023, no. 4 (124), pp. 68–73 (in Russian).

34. Kryukova N. O., Khasanova A. A., Baranova I. A., Kostinov M. P., Svitich O. A., Chuchalin A. G. Mucosal humoral immune response of respiratory tract in medical workers during the post-COVID-19 period. Rossiiskii immunologicheskii zhurnal [Russian journal of immunology], 2023, vol. 26, no. 4, pp. 633–640 (in Russian).

35. Kostinov M. P. Domestic immunotropic agents in the prevention, therapy and rehabilitation of patients with COVID-19. Мoscow, Gruppa MDV Publ., 2024. 172 p. (in Russian).